

-continued

---

Lys	Ser	Leu	Ser	Leu	Ser	Pro	Gly	Lys
210						215		

---

We claim:

1. A method of treating a subject having a tumor, the method comprising administering to the subject an effective amount of an antigen binding construct comprising:

a first antigen-binding polypeptide construct which monovalently and specifically binds a HER2 (human epidermal growth factor receptor 2) ECD2 (extracellular domain 2) region on a HER2-expressing cell and comprising a first heavy chain variable domain comprising SEQ ID NO:99 and a first light chain variable domain comprising SEQ ID NO:71, and

a second antigen-binding polypeptide construct which monovalently and specifically binds a HER2 ECD4 (extracellular domain 4) region on a HER2-expressing cell and comprising a second heavy chain variable domain comprising SEQ ID NO:305 and a second light chain variable domain comprising SEQ ID NO:297, and

first and second linker polypeptides, wherein the first linker polypeptide is operably linked to the first antigen-binding polypeptide construct, and the second linker polypeptide is operably linked to the second antigen-binding polypeptide construct;

wherein the first antigen binding polypeptide construct is a Fab and the second antigen binding polypeptide construct is an scFv, and

wherein tumor growth is decreased as compared to a control receiving an equivalent amount of a non-specific control antibody, as compared to a control receiving an equivalent amount of trastuzumab, or as compared to a control not receiving treatment; and

wherein the antigen binding construct is administered to the subject once every 7 days at a dose of at least 5 mg of antigen binding construct per kg of body weight or once every 14 days at a dose of at least 10 mg of antigen binding construct per kg of body weight or once every 14 days at a dose of at least 15 mg of antigen binding construct per kg of body weight or once every 14 days at a dose of at least 20 mg of antigen binding construct per kg of body weight or once every 21 days at a dose of at least 15 mg of antigen binding construct per kg of body weight or once every 21 days at a dose of at least 20 mg of antigen binding construct per kg of body weight.

2. The method of claim 1 wherein the antigen binding construct comprises the full length sequences of v10000 as set forth in SEQ ID NOS: 97, 295, and 69.

3. The method of claim 1, wherein the antigen binding construct consists of the full length sequences of v10000 as set forth in SEQ ID NOS: 97, 295, and 69.

\* \* \* \* \*